The open-label, multi-center, randomized Phase 2b clinical study conducted in France assessed the efficacy of eryaspase, a drug which consists of L-asparaginase (L-ASP) encapsulated in red blood cells, as a second-line treatment in combination with chemotherapy in 141 patients with metastatic pancreatic cancer. Read more . . .
Data presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid shows that Erytech Pharma’s eyraspase (graspa) could potentially be an effective treatment in patients with metastatic pancreatic adenocarcinoma.